NALTREXONE

Search structure
Trade Names:
Synonyms:
Status: Approved (1984)
Entry Type: Small molecule
Molecule Category: Parent
ATC: N07BB04
UNII: 5S6W795CQM

Structure
InChI Key DQCKKXVULJGBQN-XFWGSAIBSA-N
Smile O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
InChI
InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C20H23NO4
Molecular Weight 341.41
AlogP 1.53
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 2.0
Polar Surface Area 70.0
Molecular species BASE
Aromatic Rings 1.0
Heavy Atoms 25.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Opioid receptors; mu/kappa/delta antagonist
Primary Target
δ receptor
κ receptor
μ receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 1 Cytochrome P450 family 1A Cytochrome P450 1A2
- - - - 1
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C19
- - - - 0
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C9
- - - - 0
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2D Cytochrome P450 2D6
- 1000 - - 36.7
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4
- - - - 0
Enzyme Hydrolase
- - - -
Ion channel Ligand-gated ion channel Nicotinic acetylcholine receptor Nicotinic acetylcholine receptor alpha subunit
- 31000-141000 - - -
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Short peptide receptor (family A GPCR) Opioid receptor
0.16-16 0.59-7500 0.05012 6.31-144 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- 157510 - - 40.3

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Alcoholism 4 D000437 ClinicalTrials
HIV Infections 3 D015658 ClinicalTrials
Obesity 3 D009765 ClinicalTrials
Pain 3 D010146 ClinicalTrials
Amphetamine-Related Disorders 3 D019969 ClinicalTrials
Heroin Dependence 3 D006556 ClinicalTrials
Substance-Related Disorders 3 D019966 ClinicalTrials
Opioid-Related Disorders 3 D009293 ClinicalTrials
Tobacco Use Disorder 3 D014029 ClinicalTrials
Cocaine-Related Disorders 3 D019970 ClinicalTrials
Gambling 3 D005715 ClinicalTrials
Stress Disorders, Post-Traumatic 3 D013313 ClinicalTrials
Borderline Personality Disorder 3 D001883 ClinicalTrials
Endometriosis 3 D004715 ClinicalTrials
Chronic Pain 3 D059350 ClinicalTrials
Opioid-Related Disorders 3 D009293 ClinicalTrials
Depressive Disorder 3 D003866 ClinicalTrials
Multiple Sclerosis 3 D009103 ClinicalTrials
Cocaine-Related Disorders 3 D019970 ClinicalTrials
Alcohol Drinking 2 D000428 ClinicalTrials
Respiratory Distress Syndrome 2 D012128 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Depressive Disorder, Major 2 D003865 ClinicalTrials
Colitis, Ulcerative 2 D003093 ClinicalTrials
Crohn Disease 2 D003424 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Depressive Disorder, Major 2 D003865 ClinicalTrials
Marijuana Abuse 2 D002189 ClinicalTrials
Dry Eye Syndromes 2 D015352 ClinicalTrials
Alcohol-Related Disorders 2 D019973 ClinicalTrials
Cystitis, Interstitial 2 D018856 ClinicalTrials
Back Pain 2 D001416 ClinicalTrials
Diabetic Neuropathies 2 D003929 ClinicalTrials
Post-Acute COVID-19 Syndrome 2 D000094024 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Fibromyalgia 2 D005356 ClinicalTrials
Low Back Pain 2 D017116 ClinicalTrials
Fatigue 2 D005221 ClinicalTrials
Coronavirus Infections 2 D018352 ClinicalTrials
Migraine Disorders 2 D008881 ClinicalTrials
Trichotillomania 2 D014256 ClinicalTrials
Obsessive-Compulsive Disorder 2 D009771 ClinicalTrials
Bulimia 1 D002032 ClinicalTrials
Psoriasis 1 D011565 ClinicalTrials
Child Development Disorders, Pervasive 1 D002659 ClinicalTrials
Smoking Cessation 1 D016540 ClinicalTrials
Schizophrenia 1 D012559 ClinicalTrials
Bulimia Nervosa 1 D052018 ClinicalTrials
Anorexia Nervosa 1 D000856 ClinicalTrials
Dermatitis, Atopic 1 D003876 ClinicalTrials
Mental Disorders 1 D001523 ClinicalTrials
Melanoma 1 D008545 ClinicalTrials

Related Entries

MCS

Scaffolds

Salt

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
26.13
Injury, poisoning and procedural complications
17.9
Psychiatric disorders
15.85
Nervous system disorders
8.99
Gastrointestinal disorders
5.79
Musculoskeletal and connective tissue disorders
4.31
Skin and subcutaneous tissue disorders
3.54
Respiratory, thoracic and mediastinal disorders
2.17
Investigations
2.07
Vascular disorders
2.04

Cross References

Resources Reference
CAS NUMBER 16590-41-3
ChEBI 7465
ChEMBL CHEMBL19019
DrugBank DB00704
DrugCentral 1765
EPA CompTox DTXSID4046313
FDA SRS 5S6W795CQM
Human Metabolome Database HMDB14842
Guide to Pharmacology 1639
KEGG C07253
PharmGKB PA450588
PubChem 5360515
SureChEMBL SCHEMBL34681
ZINC ZINC000000001773
CONTENTS